237 related articles for article (PubMed ID: 37378881)
21. The promise and peril of KRAS G12C inhibitors.
Moore AR; Malek S
Cancer Cell; 2021 Aug; 39(8):1059-1061. PubMed ID: 34375610
[TBL] [Abstract][Full Text] [Related]
22. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
Lee A
Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
[TBL] [Abstract][Full Text] [Related]
23. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
24. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
[TBL] [Abstract][Full Text] [Related]
25. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
Lindsay CR; Garassino MC; Nadal E; Öhrling K; Scheffler M; Mazières J
Lung Cancer; 2021 Oct; 160():152-165. PubMed ID: 34417059
[TBL] [Abstract][Full Text] [Related]
26. Amplification of Wild-type
Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
[TBL] [Abstract][Full Text] [Related]
27. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
28. Molecular profile of KRAS G12C-mutant colorectal and non-small-cell lung cancer.
Araujo LH; Souza BM; Leite LR; Parma SAF; Lopes NP; Malta FSV; Freire MCM
BMC Cancer; 2021 Feb; 21(1):193. PubMed ID: 33632153
[TBL] [Abstract][Full Text] [Related]
29. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer.
Wang H; Lv Q; Xu Y; Cai Z; Zheng J; Cheng X; Dai Y; Jänne PA; Ambrogio C; Köhler J
EBioMedicine; 2019 Nov; 49():106-117. PubMed ID: 31668570
[TBL] [Abstract][Full Text] [Related]
30. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic/nongenetic mechanisms in lung cancer.
Mohanty A; Nam A; Srivastava S; Jones J; Lomenick B; Singhal SS; Guo L; Cho H; Li A; Behal A; Mirzapoiazova T; Massarelli E; Koczywas M; Arvanitis LD; Walser T; Villaflor V; Hamilton S; Mambetsariev I; Sattler M; Nasser MW; Jain M; Batra SK; Soldi R; Sharma S; Fakih M; Mohanty SK; Mainan A; Wu X; Chen Y; He Y; Chou TF; Roy S; Orban J; Kulkarni P; Salgia R
Sci Adv; 2023 Oct; 9(41):eade3816. PubMed ID: 37831779
[TBL] [Abstract][Full Text] [Related]
31. Targeting KRAS in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract][Full Text] [Related]
32. Targeting
Désage AL; Léonce C; Swalduz A; Ortiz-Cuaran S
Front Oncol; 2022; 12():796832. PubMed ID: 35251972
[TBL] [Abstract][Full Text] [Related]
33. The gRASs Is Greener: Potential New Therapies in Lung Cancer with Acquired Resistance to KRAS
Pinnelli M; Trusolino L
Cancer Discov; 2021 Aug; 11(8):1874-1876. PubMed ID: 34344756
[TBL] [Abstract][Full Text] [Related]
34. [Current status and outlook of medical treatment for
Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
[TBL] [Abstract][Full Text] [Related]
35. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J; Tímár J
Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
[TBL] [Abstract][Full Text] [Related]
36. Anticancer drug resistance: An update and perspective.
Nussinov R; Tsai CJ; Jang H
Drug Resist Updat; 2021 Dec; 59():100796. PubMed ID: 34953682
[TBL] [Abstract][Full Text] [Related]
37. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
Naim N; Moukheiber S; Daou S; Kourie HR
Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
[TBL] [Abstract][Full Text] [Related]
38. Reflections on drug resistance to KRAS
Han Z; Zhou D; Wang J; Jiang B; Liu X
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188677. PubMed ID: 35033622
[TBL] [Abstract][Full Text] [Related]
39. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC).
Rosell R; Codony-Servat J; González J; Santarpia M; Jain A; Shivamallu C; Wang Y; Giménez-Capitán A; Molina-Vila MA; Nilsson J; González-Cao M
Crit Rev Oncol Hematol; 2024 Mar; 195():104228. PubMed ID: 38072173
[TBL] [Abstract][Full Text] [Related]
40. Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics.
Zhang Y; Zeng F; Peng S; Chen Y; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Yan H; Zhang X; Zhang L; Yang N; Gong Q; Zeng L; Zhang Y
Expert Rev Respir Med; 2023; 17(9):743-751. PubMed ID: 37776047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
